Cite
Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
MLA
Sholler, Dennis J., et al. “Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.” Journal of Analytical Toxicology, vol. 46, no. 5, June 2022, pp. 494–503. EBSCOhost, https://doi.org/10.1093/jat/bkab059.
APA
Sholler, D. J., Spindle, T. R., Cone, E. J., Goffi, E., Kuntz, D., Mitchell, J. M., Winecker, R. E., Bigelow, G. E., Flegel, R. R., & Vandrey, R. (2022). Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. Journal of Analytical Toxicology, 46(5), 494–503. https://doi.org/10.1093/jat/bkab059
Chicago
Sholler, Dennis J, Tory R Spindle, Edward J Cone, Elia Goffi, David Kuntz, John M Mitchell, Ruth E Winecker, George E Bigelow, Ronald R Flegel, and Ryan Vandrey. 2022. “Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.” Journal of Analytical Toxicology 46 (5): 494–503. doi:10.1093/jat/bkab059.